Tolerx Announces Achievement Of Milestones Upon Anti-CD4 Antibody Program Advancement And Initiation Of Phase 1 Clinical Trial

Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases, announced that Genentech, a collaborator, has moved a modified version of TRX1, MTRX1011A, an anti-CD4 monoclonal antibody, into a phase 1 clinical trial that has begun enrolling patients. The clinical trial is evaluating the safety and tolerability of both single and multiple doses of MTRX1011A.

More: continued here

Filed under: Diabetes on August 11th, 2008